FGFR2 and infantile convulsions and choreoathetosis: Derazantinib is an orally bioavailable multikinase inhibitor with potent pan-FGFR activity which has shown antitumor activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy.